Related Experiment Video
Updated: Feb 12, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
C-MET inhibitors for advanced non-small cell lung cancer
Giulia Pasquini1, Giuseppe Giaccone1
1a Lombardi Comprehensive Cancer Center , Georgetown University , Washington , DC , USA.
Introduction:
The role of the c-mesenchymal-epithelial transition factor (c-MET) signaling pathway in tumor progression and invasion has been extensively studied. C-MET inhibitors have shown anti-tumor activity in NSCLC both in preclinical and in clinical trials. However, given the molecular heterogeneity of NSCLC, it is likely that only a specific subset of NSCLC patients will benefit from c-MET inhibitors. Emerging data also suggest that MET inhibitors in combination with EGFR-TKIs (epidermal growth factor receptor tyrosine kinase inhibitors) may have a role in therapy for both EGFR-TKI resistant and EGFR-TKI naïve patients. The challenges ahead are in the identification of the molecular subtypes that benefit most.
Areas Covered:
This review summarizes the current understanding of c-MET biology in relation to studies evaluating c-MET inhibitors in the treatment of NSCLC.
Expert Opinion:
MET inhibitors have the potential to benefit subsets of NSCLC patients with specific genetic alterations. Exon-14 skipping mutations appear so far to be the most promising molecular subset that is sensitive to MET inhibitors, whereas overexpression, amplification and point mutations of MET seem more challenging subgroups to target. Combination with other target agents, such as EGFR inhibitors, may represent a promising therapeutic strategy in specific areas (e.g. EGFR-TKI resistance).
Insights
C-MET inhibitors show promise for non-small cell lung cancer (NSCLC) patients with specific mutations, particularly MET exon-14 skipping. Combination therapies may overcome resistance, but identifying responsive patient subsets remains key.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The c-mesenchymal-epithelial transition factor (c-MET) signaling pathway is implicated in tumor progression and invasion.
- C-MET inhibitors have demonstrated anti-tumor activity in non-small cell lung cancer (NSCLC).
- NSCLC's molecular heterogeneity suggests only specific patient subsets will benefit from c-MET inhibitors.
Purpose of the Study:
- To review the current understanding of c-MET biology in NSCLC.
- To summarize studies evaluating c-MET inhibitors for NSCLC treatment.
- To discuss challenges and future directions in targeting c-MET in NSCLC.
Main Methods:
- Literature review of preclinical and clinical studies on c-MET inhibitors in NSCLC.
- Analysis of molecular alterations associated with c-MET signaling.
- Evaluation of combination therapy strategies involving c-MET inhibitors.
Main Results:
- MET inhibitors show potential benefit in NSCLC patients with specific genetic alterations, notably MET exon-14 skipping mutations.
- Overexpression, amplification, and point mutations of MET present more challenging targets.
- Combination therapy with EGFR inhibitors may be effective for both EGFR-TKI resistant and naïve NSCLC patients.
Conclusions:
- C-MET inhibitors offer a targeted therapy option for specific NSCLC molecular subtypes.
- Identifying responsive patient populations is crucial for effective c-MET inhibitor therapy.
- Combination strategies, particularly with EGFR inhibitors, hold promise for overcoming treatment resistance.
More Related Videos
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
01:52Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
01:47Lung Capacity
02:22Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
00:56Extraction: Advanced Methods
01:35Cancer Cell Migration through Invadopodia
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...